

R H I N O M E D

RHINOMED BOARD CHANGES

- **Rhinomed appoints Consumer Health Leader Lyn Swinburne AO to its Board.**
- **Dr Eric Knight to retire as Non-Executive Director.**

8th September 2022: Melbourne, Australia.

Rhinomed Limited (ASX:RNO OTCQB:RHNMF), a leader in wearable nasal and respiratory technology including nasal diagnostics, is pleased to announce the appointment of Ms Lyn Swinburne AO, one of Australia's most experienced consumer-led health leaders, as a Non-Executive Director of Rhinomed.

Ms Swinburne is the founder of Breast Cancer Network Australia, the nation's most successful consumer-led health organisation with over 160,000 network members. Over the course of her career she has revolutionised awareness of breast cancer and driven a fundamental change to patient-centred care for breast cancer sufferers. She is internationally recognised as a pioneer and leader in developing best practice models for consumer input into health research, policy, services and commercial outcomes. An experienced Non-Executive Director in the corporate and not-for-profit sectors, Ms Swinburne recently stepped down after nine years as Chair of the Board of the Royal Women's Hospital, Melbourne.

"We look forward to Lyn bringing her extensive experience in advocacy for patient-led health innovation, rapid organisational growth, brand building and a deep and sophisticated understanding of health policy and health systems to our growing medical technology company," said Chair Ron Dewhurst.

Ms Swinburne's contribution to the Australian health sector has been acknowledged with numerous awards including the Order of Australia 2018, Honorary Doctorate (Social Sciences) Swinburne University 2015, Australian of the Year finalist 2006, Melburnian of the Year 2007, Equity Trustees' Not-for-Profit CEO of the Year Award 2004, The Centenary Federation Medal 2003, Victorian Women's Honour Role 2002. She was also one of the Australian Financial Review/Westpac's Australian 100 Women of Influence in 2016, and was the winner of the Social Enterprise & Not-for-Profit Category of the 100 Women of Influence Award 2016.

Dr Eric Knight has also announced his intention to retire from Rhinomed's Board after 8 and a half years of service as a Non-Executive Director. During that time, Dr Knight has provided key input as Rhinomed developed its strategy, across products, distribution channels, and markets. "I take this opportunity to thank Eric for his great contribution to Rhinomed over the last eight years as Rhinomed has expanded into international markets and diversified its technology platform. We sincerely thank Eric for his exemplary service and support of Rhinomed," said Mr Dewhurst. Dr Knight's retirement will be effective from 30 September 2022.

R H I N O M E D

This report has been authorised for release to the market by the Board.

Company	Investor and Media Relations
Michael Johnson, CEO & Director +61 (0) 3 8416 0900 mjohnson@rhinomed.global Follow us on Twitter @rhinomedceo	Rudi Michelson Monsoon Communications +61(0) 411 402 737 rudim@monsoon.com.au

About Rhinomed Limited (ASX: RNO, OTCQB:RHNMF)

Rhinomed Limited is a nasal and airway technology company developing and selling innovative products that improve breathing, help the diagnosis of upper respiratory diseases and potentially enable more effective drug delivery. Rhinomed has a range of FDA, TGA and CE Mark registered nasal devices on the market that improve breathing (including for athletes), sleep and snoring, with increasing global sales in thousands of retail and online outlets. This includes Mute, the leading internal anti-snoring nasal dilator in the USA, which grew its sales 4on Amazon by 156% in 2022.

Rhinoswab is a more comfortable, reliable nasal swab for sample self-collection for testing COVID-19 and other respiratory viruses. This is Rhinomed's entry into the diagnostics market. In multiple user trials Rhinoswab was the preferred swab by over 75% of users and highly rated on comfort. Its companion product, the child friendly Rhinoswab Junior, has also proven to be effective and strongly preferred by children, parents and nurses in trials by the Murdoch Children's Research Institute and Royal Children's Hospital, Melbourne. The Rhinoswab range is registered with the FDA, MHRA, TGA and awarded a CE Mark with registrations pending in other markets.